Transgene S.A. (TNG) is a Biotechnology company in the Healthcare sector, listed on Euronext Paris. This page provides the complete earnings calendar, dividend schedule, and financial data for Transgene S.A. in 2026. The next earnings report is expected on September 24, 2026.
Next earnings date
24 Sep 2026
In 36 days
EPS estimate
—
Revenue estimate
—
Past earnings
No dividend history available.
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Transgene S.A. (TNG) is scheduled to report earnings on September 24, 2026.
Transgene S.A. (TNG) last reported earnings on September 16, 2025.
Transgene S.A. (TNG) is listed on Euronext Paris.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.